Pfizer, Astellas' Xtandi combo cuts risk of death by 58% in prostate cancer patients

Pfizer, Astellas' Xtandi combo cuts risk of death by 58% in prostate cancer patients

Submitted by admin on May 1, 2023 - 10:13am
Source: 
Seeking Alpha
News Tags: 
Pfizer
Astellas
Xtandi
prostate cancer
clinical trials
Headline: 
Pfizer, Astellas' Xtandi combo cuts risk of death by 58% in prostate cancer patients
snippet: 
Pfizer (PFE) and Astellas Pharma (ALPMF) (ALPMY) Xtandi combo reduced the risk of death by 58% in patients with prostate cancer in a trial.

Do Not Allow Advertisers to Use My Personal information